Intranasal 15D-Pgj2 Ameliorates Brain Glucose Hypometabolism Via PPAR-dependent Activation of PGC-1/GLUT4 Signalling in APP/PS1 Transgenic Mice
Zongyang Li,Yuan Zhang,Yueyang Zheng,Wenlan Liu,Xiejun Zhang,Weiping Li,Di Zhang,Qian Cai,Sicen Wang,Xiangbao Meng,Guodong Huang
DOI: https://doi.org/10.1016/j.neuropharm.2021.108685
IF: 5.273
2021-01-01
Neuropharmacology
Abstract:Targeting the common molecular mechanism of type 2 diabetes mellitus and Alzheimer's disease (AD), including dysregulation of glucose metabolism, insulin resistance, and neuroinflammation, might be an efficient treatment strategy for AD. Previous studies have shown that 15-deoxy-Delta 12,14-prostaglandin J2 (15d-PGJ2), an endogenous PPAR gamma agonist, has anti-inflammatory, insulin sensitizing and anti-diabetic effects. However, whether 15d-PGJ2 has beneficial effects on AD remains to be elucidated. In the present study, we found that intranasal administration of 15d-PGJ2 (300 ng/30 mu L/day) for 3 months significantly inhibited A beta plaques, suppressed neuroinflammation, and attenuated cognitive deficits in APP/PS1 transgenic mice. Interestingly, 15d-PGJ2 treatment could increase brain glucose uptake, as detected by F-18-FDG microPET imaging, and co-localization of GLUT4 and NeuN in the hippocampus of APP/PS1 mice. Furthermore, 15d-PGJ2 markedly increased the expression of PPAR gamma and PGC-1 alpha, upregulated GLUT4, and decreased the phosphorylation of IRS-1 (Ser616) in the hippocampus of APP/PS1 mice. Importantly, co-administration of a PPAR gamma antagonist GW9662 abrogated these protective effects of 15d-PGJ2. Collectively, intranasal 15d-PGJ2 conferred protective effects against AD by activating PPAR gamma-dependent PGC-1 alpha/GLUT4 signalling. The PPAR gamma agonist 15d-PGJ2 might be a potential therapeutic drug for AD.